An Interesting Case of COVID-19 related Parkinsonism
Objective: Virus related Parkinsonism causing encephalitis lethargica has been documented in the literature. The novel Coronavirus (COVID-19) has been linked to a small number of…The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
Objective: To investigate whether NLX-112, a potent and selective 5-HT1A agonist is neuroprotective in a mouse MPTP model of Parkinson’s Disease (PD) [1]. Background: There…Diagnosis of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy with 7T-MRI substantia nigra imaging
Objective: To detect the signal change of nigrosome-1 in 7T-MRI and its diagnostic and differential diagnostic efficacy as the imaging biomarker of PD, MSA-P, MSA-C…Case report- Cavernoma involving substantia nigra and nigrostriatal pathway as a rare cause of secondary parkinsonism with a 3 year follow up
Objective: To describe a case report of a rare cause of Parkinsonism Background: Vascular malformations such as cerebral cavernomas are known to predispose to haemorrhagic…An in-vivo study of the integrity of the nigrostriatal pathways in drug-naive Parkinson’s disease patients using [11C]PE2I PET and neuromelanin-Magnetic Resonance Imaging
Objective: This study evaluated the relationship between the neurodegeneration of the substantia nigra neurons, assessed using Neuromelanin-sensitive MRI, and of the loss of striatal dopaminergic…Agreement between swallow tail sign asymmetry and clinical laterality in Parkinson’s disease
Objective: Our goal was to evaluate the concordance between asymmetry in nigral hyperintensity detected with 3T MRI and clinical symptomatology. Background: A promising MRI marker…Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial
Objective: To select the most effective number of repeat doses of mesenchymal stem cells (MSC) delivered intravenously to slow the progression of Parkinson’s disease (PD).…Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?
Objective: To determine if GDNF receptor expression levels in the striatum or substantia nigra (SN) change in relation to differences in tyrosine hydroxylase (TH) and…Sex differences for clinicopathological correlations in people with Lewy body pathology
Objective: To determine sex-specific clinical correlations of different Lewy body (LB), Alzheimer’s disease (AD) pathology staging and nigral neuron loss levels in people with LB…Fibrinogen and CFAH: The two putative markers of Parkinson’s disease with cognitive impairment
Objective: To determine the pathogenic potential of fibrinogen and complement factor H (CFAH) in causing Parkinson’s disease (PD) with cognitive impairment (PDCI)-like symptoms using C57BL/6J…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »